Form 51-102F3 MATERIAL CHANGE REPORT

Item 1: Name and Address of Company

THC BioMed Intl Ltd. (the "Issuer")
P.O. Box 20033 Towne Centre
Kelowna, BC V1Y 9H2

Item 2: Date of Material Change

April 6, 2018

Item 3: News Release

A news release was disseminated on April 6, 2018 and filed on SEDAR (www.sedar.com) and the Canadian Securities Exchange (the "CSE"). A copy of the news release is attached as Schedule "A" hereto.

Item 4: Summary of Material Change

The Issuer announced that it closed the purchase of a building located in downtown Kelowna for a total of \$1,922,273. The Issuer purchased the property for cash and did not require a mortgage. The building consists of two stories and has 8000 sq. feet of space which will be used to set up the Issuer's first brick and mortar dispensary and will house the corporate offices and a laboratory.

Item 5: Full Description of Material Change

Please see the attached Schedule "A".

Item 6: Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable

Item 7: Omitted Information

None

Item 8: Executive Officer

John Miller, CEO and President Email: info@thcbiomed.com

Item 9: Date of Report

April 10, 2018

Schedule "A"



THC BIOMED INTL LTD.
P.O. Box 20033 Towne Centre
Kelowna, B.C. V1Y 9H2
www.thcbiomed.com

THC Completes Purchase of Building in Downtown Kelowna

THC.CSE THCBF – OTC TFHC.F

Vancouver, British Columbia – (April 6, 2018) THC BioMed Intl Ltd. (CSE: THC), ("THC" or the "Company") is pleased to announce that, further to its news release of April 4, 2018, it closed the purchase of a building located in downtown Kelowna for a total of \$1,922,273. THC purchased the property for cash and did not require a mortgage. The building consists of two stories and has 8000 sq. feet of space which will be used to set up THC's first brick and mortar dispensary and will house the corporate offices and a laboratory.

About THC

THC is an ACMPR Licensed Producer and a supplier of legal Cannabis Genetics. THC also produces and sells dried and fresh marijuana and cannabis oil for medical purposes. THC is also active in scientific research and the development of products and services related to the medical cannabis industry. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry.

Please visit our website for a more detailed description of our business and services available. www.thcbiomed.com

President and CEO:

John Miller

THC Biomed Intl Ltd. T: 1-844-THCMEDS

E: info@thcbiomed.com

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC. Forward-looking information is based on certain key expectations and assumptions made by the management of THC. In some cases, you can identify forward-looking statements by the use of words such as "will," "may," "would," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "could" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release and include that: (a) the building will be used to set up THC's first brick and mortar dispensary and will also house the corporate offices and a laboratory; and (b) THC will be in the forefront of this rapidly growing industry.

THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.